PHARMAJET
PharmaJet is a Golden, Colorado-based commercial-stage MedTech company that develops WHO-prequalified, FDA-cleared, and CE-marked spring-powered needle-free jet injection systems (Tropis, Stratis) for vaccines and therapeutics, serving pharmaceutical/biotech partners and global immunization programs across 20+ million administered doses.
- Company typePrivate
- Founded2005
- HeadquartersGolden, United States
- Headcount11–50
- GTM typeB2B
- OfferingHardware or Manufacturing
What PHARMAJET does
PharmaJet is a commercial-stage medical device company founded in 2005 and headquartered in Golden, Colorado, that develops spring-powered needle-free jet injection systems for vaccines and injectable therapeutics. Its two commercial product lines, Tropis (0.1 mL intradermal) and Stratis (0.5 mL intramuscular/subcutaneous), deliver a fixed-dose fluid jet in approximately 1/10 of a second without needles, sharps, or external power. Both systems have achieved WHO PQS prequalification, CE Mark, and (for Stratis) FDA 510(k) clearance, enabling procurement by UN agencies and global immunization programs.
The company's business model combines direct hardware sales of reusable devices and disposable sterile syringes with technology licensing and co-development agreements with pharmaceutical and biotechnology partners. It has supplied more than 20 million needle-free injections globally across polio eradication campaigns in Pakistan, Nigeria, Afghanistan, Somalia, and Egypt, and supports 50+ active studies and 80+ completed studies with named partners including Scancell, Nykode, Gennova, Zydus, and Immuno Cure across oncology, infectious disease, and DNA/mRNA vaccine platforms.
PharmaJet operates a hybrid B2B MedTech go-to-market combining direct enterprise sales to pharmaceutical/biotech companies, channel distribution (notably with EVA Pharma/ATR in the Middle East and Africa), and institutional partnerships with global health organizations (WHO, Gates Foundation, PATH, CDC, AFENET, USAID). The company maintains regulatory, clinical, and commercial infrastructure spanning 11–50 employees and is currently expanding into self-injection pens for home use in chronic disease management, funded in part by a 2023 strategic investment from Japan's Daicel Corporation.
PHARMAJET firmographics
Firmographics- Name
- PHARMAJET
- Legal name
- PharmaJet, Inc.
- Website
- https://pharmajet.com
- Company type
- Private
- Founded year
- 2005
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- PharmaJet is a Golden, Colorado-based commercial-stage MedTech company that develops WHO-prequalified, FDA-cleared, and CE-marked spring-powered needle-free jet injection systems (Tropis, Stratis) for vaccines and therapeutics, serving pharmaceutical/biotech partners and global immunization programs across 20+ million administered doses.
- Ownership category
- akta.pro rank
PHARMAJET industry classification
Industry- Product category
- Needle-free injection medical devices
- NAICS
- Surgical and Medical Instrument Manufacturing (339112)
- SIC
- Surgical & Medical Instruments & Apparatus (3841)
- akta.pro primary industry
- Needle-Free Injection Systems (Jet Injectors/Microneedle Patches) (HLAHAIAD)
- akta.pro secondary industry
- Vaccine Delivery & Administration Systems (needle-free, microneedle patches, intranasal/oral) (HLAAAEAF)
Keywords
Where PHARMAJET is headquartered
LocationHeadquarters
- HQ city
- Golden
- HQ country
- United States
- HQ region
- North America
Offices1 record
Markets served
PHARMAJET business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Personnel, Supply Chain, Operations, Technology or R&D, Marketing or Sales, Infrastructure
Revenue model
- Medical Device Hardware Sales: PharmaJet generates revenue through the sale of its needle-free injection systems (Tropis and Stratis devices) and associated sterile, auto-disabling syringes. The company sells directly to healthcare providers, pharmaceutical partners, and through distribution agreements with regional partners. Pricing is comparable to traditional needle injections with reduced dose volume enabling cost savings for intradermal delivery.
- Technology Licensing and Partnership Agreements: Revenue generated through strategic partnerships with pharmaceutical and biotechnology companies where PharmaJet's technology is used for partner product delivery. This includes co-development agreements, technology transfer arrangements, and potentially milestone payments tied to clinical and commercialization progress.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Unit Pricing | Pay-as-you-go | Comparable to needle and syringe pricing |
Go-to-market motion2 records
Distribution channels3 records
Marketing channels6 records
PHARMAJET product offering
Product offeringCore offering
PharmaJet develops and manufactures spring-powered needle-free jet injection systems for delivering vaccines and therapeutics without needles. Its two commercial systems are the Tropis ID device for 0.1 mL intradermal injections and the Stratis IM/SC device for 0.5 mL intramuscular and subcutaneous injections, both cleared by FDA, CE Marked, and WHO PQS prequalified, with reusable auto-disabling syringe components sold alongside the devices.
Product overview
PharmaJet offers a portfolio of commercial-stage needle-free injection systems consisting of two core products: the Tropis® ID system for 0.1 mL intradermal delivery and the Stratis® IM/SC system for 0.5 mL intramuscular and subcutaneous injections. Both systems are spring-powered devices that deliver medications through a narrow high-velocity fluid jet in approximately 0.1 seconds without needles. The company is also developing needle-free self-injection pens for home use targeting chronic disease management. All products share the core needle-free delivery technology platform, with variations in dose volume and injection depth to serve different therapeutic applications.
Differentiator
Problem solved
Functional benefit
Brands
- Tropis: Needle-free Injection System for 0.1 mL intradermal injections. WHO prequalified, CE marked device for precise intradermal delivery.
- Stratis
- Precision Delivery Systems
Products and services
- Tropis ID Needle-free Injection System A spring-powered needle-free injection system that delivers a precise 0.1 mL intradermal dose in approximately 1/10 of a second, designed for intradermal vaccine and therapeutic delivery. WHO prequalified and CE Mark certified, used in polio immunization campaigns and clinical vaccine delivery globally.
- Stratis IM/SC Needle-free Injection System A spring-powered needle-free injection system for 0.5 mL intramuscular and subcutaneous injections, used to deliver medications and vaccines. Has U.S. FDA 510(k) marketing clearance, CE Mark, and WHO PQS certification.
- Needle-free Self-Injection Pens Proprietary reusable needle-free self-injector pens being developed for home use, designed to improve patient compliance and address needle aversion, particularly for chronic disease management and metabolic peptide therapies.
Quantifiable outcome
- 87% of recipients report no pain with Tropis; 69% reduced soreness compared to needles
- +8 more outcomes
Companies that use PHARMAJET
Customer profileNamed customers9 records
Segments4 records
Ideal customer profiles3 records
PHARMAJET technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature4 records
PHARMAJET partnerships and signals
Strategic signalPartnerships
Eleven partnerships are on record, tiered core and secondary.
- African Field Epidemiology Network (AFENET)corePartnership with AFENET to deploy Tropis ID needle-free injection system for delivering approximately 1.4 million doses of fractional inactivated polio vaccine (fIPV) during polio immunization campaigns in Nigeria. AFENET collaborates with ministries of health to implement polio eradication initiatives.
- Brazilian Tuberculosis Research Network (REDE-TB)secondaryClinical study agreement to evaluate Tropis ID needle-free injection device as delivery system for tuberculin skin test. Study will assess accuracy, workflow efficiency, safety, and acceptability compared to traditional needle and syringe administration.
- EVA Pharma (ATR Affiliate)coreDistribution agreement signed at CPHI meeting in Frankfurt for Tropis needle-free injection systems covering Egypt and Middle East and Africa region. Collaboration aims to improve immunization coverage, reduce costs, and increase vaccine acceptance through Tropis distribution, technology transfer, and local manufacturing.
- Immuno CuresecondaryAgreement for clinical development of HIV therapeutic DNA vaccine (ICVAX) delivered via PharmaJet Tropis needle-free injection system. Aims to evaluate safety and immunogenicity in human clinical study.
- ScancellcorePartnership for development and commercialization of SCIB1/iSCIB1+ DNA immunotherapy for advanced melanoma using PharmaJet Stratis needle-free delivery. Phase 2 clinical data showed positive results; advancing to late-stage clinical development.
- Nykode TherapeuticscorePharmaJet delivery systems used in multiple Nykode clinical trials for cancer vaccines targeting cervical cancer, head and neck cancers, and metastatic solid tumors. Positive interim Phase 2 results announced for HPV+ cervical cancer trial.
- Gennova BiopharmaceuticalscoreGEMCOVAC-OM self-amplifying mRNA COVID-19 booster vaccine exclusively delivered with Tropis needle-free system. Received emergency use authorization in India - world's first room temperature stable mRNA vaccine.
- Zydus LifesciencescoreZyCoV-D plasmid DNA COVID-19 vaccine exclusively delivered with Tropis. World's first plasmid DNA COVID-19 vaccine for administration in humans, receiving emergency use authorization in India.
- World Health Organization (WHO)coreWHO supported development of Tropis system and awarded WHO PQS prequalification. Tropis selected for WHO polio eradication campaigns in Pakistan, Nigeria, Afghanistan, and Somalia.
- PATHcoreInternational health organization co-supported development of Tropis needle-free system. Partner on Nigeria implementation study for routine immunization using Tropis-delivered fIPV.
- CDCsecondaryU.S. Centers for Disease Control supported development of Tropis system. House-to-house campaign administration study published in MMWR.
Scale indicators8 records
Recent moves6 records
Expansion highlights6 records
PHARMAJET competitors and assessment
Company assessmentDirect peers
- Portal Instruments: Portal Instruments is developing a high-velocity jet injection platform for needle-free drug delivery, including biologic and large-volume applications. It is the most direct competitor to PharmaJet in needle-free jet injection technology, targeting pharmaceutical partners for drug-device combination products.
- INJEX Pharma: INJEX Pharma offers a spring-powered needle-free jet injection system for insulin and other injectable therapies, marketed primarily in Europe and select international markets. It directly competes with PharmaJet's Tropis and Stratis devices in the needle-free injection device category.
- Crossject: Crossject develops needle-free jet injection systems (Zeneo platform) for emergency and routine drug delivery, including vaccines and biologics. It competes with PharmaJet in the needle-free injection device category and has pursued similar partnerships with pharmaceutical companies and global health organizations.
- Antares Pharma (Halozyme): Antares Pharma, acquired by Halozyme, developed auto-injector and needle-free jet injection platforms for self-administered pharmaceuticals. It is a direct peer in the drug delivery device space serving pharmaceutical partners, though with a stronger focus on auto-injectors than pure jet injection.
- Bioject Medical Technologies: Bioject was a pioneer in needle-free jet injection technology, developing the Biojector 2000 and partnering with pharmaceutical companies for vaccine and therapeutic delivery. It is a historical direct competitor to PharmaJet in the jet injection space, though its commercial footprint has been limited.
Broad incumbents
- BD (Becton Dickinson): BD is the dominant global manufacturer of conventional needle-and-syringe injection systems, prefilled syringes, and auto-injectors used across pharmaceutical and immunization applications. It is a broad incumbent that competes with PharmaJet in the underlying drug delivery device market, including immunization programs.
- West Pharmaceutical Services: West Pharmaceutical Services is a leading provider of drug delivery device components and containment systems, including prefilled syringe and auto-injector platforms for pharmaceutical partners. It serves overlapping pharmaceutical customers as PharmaJet and is a broad incumbent in injectable drug delivery.
- Stevanato Group: Stevanato Group provides drug containment, delivery devices, and integrated solutions for pharmaceutical and biotechnology partners, including self-injection platforms. It competes with PharmaJet's emerging self-injection pen initiative and serves similar pharmaceutical customers across biologics and vaccines.
- Ypsomed: Ypsomed is a leading developer and manufacturer of self-injection pen platforms and auto-injectors for pharmaceutical and biotech partners, particularly in diabetes, obesity (GLP-1), and biologics. It is a direct competitor to PharmaJet's self-injection pen initiative for chronic disease and metabolic peptide markets.
Emerging players
- Inovio Pharmaceuticals: Inovio develops DNA vaccines and CELLECTRA electroporation delivery technology for cancer and infectious disease applications. It competes with PharmaJet in the delivery technology for next-generation DNA/mRNA vaccines, though using electroporation rather than jet injection, and serves overlapping pharmaceutical and academic research customers.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat5 records
Key risks6 records
Key highlights6 records
Customer concentration
PHARMAJET social profiles
Digital presencePHARMAJET compliance and trust
Trust signalCompliance4 records
PHARMAJET financial estimates
Financial estimateRevenue estimate
Valuation estimate
PHARMAJET leadership team
Management profileNumber of profiles
Profiles16 records
PHARMAJET funding detail
Funding detailFunding overview
Funding rounds16 records
Investors7 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
PHARMAJET M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about PHARMAJET
What does PHARMAJET do?
PharmaJet develops and manufactures spring-powered needle-free jet injection systems for delivering vaccines and therapeutics without needles. Its two commercial systems are the Tropis ID device for 0.1 mL intradermal injections and the Stratis IM/SC device for 0.5 mL intramuscular and subcutaneous injections, both cleared by FDA, CE Marked, and WHO PQS prequalified, with reusable auto-disabling syringe components sold alongside the devices.
Is PHARMAJET a public or private company?
PHARMAJET is a private company. It is classified as venture growth investor backed and is currently operating.
When was PHARMAJET founded?
PHARMAJET was founded in 2005. It employs 11 to 50 people.
Where is PHARMAJET based?
PHARMAJET is headquartered in Golden, United States, in the North America region.
How does PHARMAJET make money?
Two revenue lines are on record. Medical Device Hardware Sales are the primary driver. The others are technology Licensing and Partnership Agreements.
Who are PHARMAJET's main competitors?
Direct peers on record are Portal Instruments, INJEX Pharma, Crossject, Antares Pharma (Halozyme) and Bioject Medical Technologies. Broad incumbents are BD (Becton Dickinson), West Pharmaceutical Services, Stevanato Group and Ypsomed. Inovio Pharmaceuticals is listed as an emerging player.
Does PHARMAJET have an API?
No public API is recorded for PHARMAJET.
What industry is PHARMAJET in?
PHARMAJET's product category is Needle-free injection medical devices. Its primary akta.pro industry code is HLAHAIAD, Needle-Free Injection Systems (Jet Injectors/Microneedle Patches), with a secondary code of HLAAAEAF, Vaccine Delivery & Administration Systems (needle-free, microneedle patches, intranasal/oral). Its NAICS code is 339112 and its SIC code is 3841.